These results suggest that FASN-mediated mutp53 palmitoylation is an important mechanism underlying mutp53 accumulation and GOF, and most importantly, targeting FASN is a potential therapeutic strategy for cancers carrying mutp53 (Fig. 7f). Here, FASN is linked to cancer.